Renovaro Biosciences Inc RENB

NAS: RENB | ISIN: US29350E1047 12/05/2025

0,323 USD (+2,38%)

(+2,38%) 12/05/2025

Toon enkel gratis nieuws

4 april 2025 · Renovaro Provides Update to Definitive Agreement with Predictive Oncology · Persbericht

3 maart 2025 · Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology · Persbericht

26 februari 2025 · Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine · Persbericht

26 februari 2025 · Renovaro Announces $15 million in Equity Committed · Persbericht

7 januari 2025 · Renovaro Appoints Nathen Fuentes as Chief Financial Officer · Persbericht

7 januari 2025 · Renovaro Issues Shareholder Letter and Provides Corporate Update · Persbericht

6 januari 2025 · Renovaro to Acquire Predictive Oncology in All-Stock Transaction · Persbericht

30 december 2024 · Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV · Persbericht

23 december 2024 · RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program · Persbericht

20 december 2024 · Renovaro Regains Compliance with NASDAQ Listing Requirement · Persbericht

20 december 2024 · Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection · Persbericht

29 september 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APRN, RENB, TALS, WMC · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe